MY206327A - Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile - Google Patents

Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Info

Publication number
MY206327A
MY206327A MYPI2021003795A MYPI2021003795A MY206327A MY 206327 A MY206327 A MY 206327A MY PI2021003795 A MYPI2021003795 A MY PI2021003795A MY PI2021003795 A MYPI2021003795 A MY PI2021003795A MY 206327 A MY206327 A MY 206327A
Authority
MY
Malaysia
Prior art keywords
formulations
quinazolin
benzonitrile
oxo
isopropyl
Prior art date
Application number
MYPI2021003795A
Other languages
English (en)
Inventor
Kalliopi Stasi
Michela Montecchi-Palmer
Muneto Mogi
Quintus Medley
Chinmay Maheshwari
Joseph Paul Bullock
Original Assignee
Bausch & Lomb Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb Ireland Ltd filed Critical Bausch & Lomb Ireland Ltd
Publication of MY206327A publication Critical patent/MY206327A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
MYPI2021003795A 2019-02-15 2020-02-13 Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile MY206327A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806705P 2019-02-15 2019-02-15
PCT/IB2020/051211 WO2020165839A1 (en) 2019-02-15 2020-02-13 Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Publications (1)

Publication Number Publication Date
MY206327A true MY206327A (en) 2024-12-11

Family

ID=69740424

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021003795A MY206327A (en) 2019-02-15 2020-02-13 Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Country Status (23)

Country Link
US (4) US11478480B2 (cg-RX-API-DMAC10.html)
EP (1) EP3923912A1 (cg-RX-API-DMAC10.html)
JP (5) JP6994061B2 (cg-RX-API-DMAC10.html)
KR (2) KR20260057219A (cg-RX-API-DMAC10.html)
CN (2) CN111568906B (cg-RX-API-DMAC10.html)
AU (2) AU2020220957B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021015737A2 (cg-RX-API-DMAC10.html)
CA (1) CA3130237A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002153A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021010689A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210428A (cg-RX-API-DMAC10.html)
EC (1) ECSP21059628A (cg-RX-API-DMAC10.html)
IL (1) IL284628A (cg-RX-API-DMAC10.html)
JO (1) JOP20210224A1 (cg-RX-API-DMAC10.html)
MX (2) MX2021009704A (cg-RX-API-DMAC10.html)
MY (1) MY206327A (cg-RX-API-DMAC10.html)
PE (1) PE20212106A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021551967A1 (cg-RX-API-DMAC10.html)
SA (1) SA521430043B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202107259QA (cg-RX-API-DMAC10.html)
TW (1) TWI827800B (cg-RX-API-DMAC10.html)
WO (1) WO2020165839A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202104594B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200261456A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
WO2021191273A1 (en) * 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US12459902B2 (en) * 2020-08-06 2025-11-04 Bausch + Lomb Ireland Limited Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
TW202222298A (zh) * 2020-10-07 2022-06-16 瑞士商諾華公司 含有可溶解的眼部插入物之藥物及其使用方法
US20230159202A1 (en) * 2021-11-23 2023-05-25 Bausch + Lomb Ireland Limited Method for making a preservative-free packaged ophthalmic device product
US20240197691A1 (en) * 2022-12-15 2024-06-20 Cn2 Therapeutics, Inc. Tacrolimus compositions and methods of use
CN118340775A (zh) * 2023-01-09 2024-07-16 维眸生物科技(浙江)有限公司 一种含vvn539的眼用组合物及其用途
EP4454639A1 (en) * 2023-04-14 2024-10-30 Omnivision GmbH Ophthalmic composition comprising carbomer and taurine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
DE60006262T2 (de) * 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20100152209A1 (en) 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP2009521484A (ja) 2005-12-22 2009-06-04 プロレキシーズ ファーマシューティカルズ インコーポレイテッド ３−アリール置換キナゾロンおよびその使用
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
EP1964548A1 (en) 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
ES2648225T3 (es) 2007-07-18 2017-12-29 Novartis Ag Combinaciones sinérgicas de antagonistas de VR-1 e inhibidores de COX-2
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
WO2009089057A1 (en) 2008-01-09 2009-07-16 Renovis, Ins. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
EP2694048B1 (en) * 2011-04-05 2020-10-07 Optosolve Research & Development Ltd Ophthalmic treatments
CN102659629B (zh) * 2012-02-14 2014-03-19 杭州华东医药集团新药研究院有限公司 化合物及其在制备埃罗替尼中的用途
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
ES2951202T3 (es) 2014-07-28 2023-10-19 Sun Pharma Advanced Res Co Ltd Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
HUE048564T2 (hu) * 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
AU2017330620A1 (en) 2016-09-20 2019-03-28 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
JP2019532054A (ja) 2016-09-20 2019-11-07 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
US20200261456A1 (en) 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain

Also Published As

Publication number Publication date
JOP20210224A1 (ar) 2023-01-30
ECSP21059628A (es) 2021-09-30
AU2020220957B2 (en) 2023-04-06
MX2024002989A (es) 2024-03-27
CN111568906B (zh) 2023-09-01
JP7860054B2 (ja) 2026-05-15
JP7465453B2 (ja) 2024-04-11
JP2022017260A (ja) 2022-01-25
EP3923912A1 (en) 2021-12-22
CR20210428A (es) 2021-09-22
JP6994061B2 (ja) 2022-01-14
US11478480B2 (en) 2022-10-25
US20260034132A1 (en) 2026-02-05
TWI827800B (zh) 2024-01-01
JP2024095674A (ja) 2024-07-10
JP2020132634A (ja) 2020-08-31
TW202045178A (zh) 2020-12-16
US20200261457A1 (en) 2020-08-20
US12290517B2 (en) 2025-05-06
SA521430043B1 (ar) 2022-11-20
CA3130237A1 (en) 2020-08-20
CL2021002153A1 (es) 2022-04-18
MX2021009704A (es) 2021-09-14
US20200390767A1 (en) 2020-12-17
JP2022520795A (ja) 2022-04-01
KR20210127197A (ko) 2021-10-21
PH12021551967A1 (en) 2022-05-23
AU2020220957A1 (en) 2021-08-05
BR112021015737A2 (pt) 2021-10-26
IL284628A (en) 2021-08-31
AU2023203933B2 (en) 2025-06-12
CN117752662A (zh) 2024-03-26
AU2023203933A1 (en) 2023-07-13
US20230139170A1 (en) 2023-05-04
WO2020165839A1 (en) 2020-08-20
SG11202107259QA (en) 2021-08-30
ZA202104594B (en) 2024-10-30
WO2020165839A9 (en) 2021-03-18
PE20212106A1 (es) 2021-11-04
CN111568906A (zh) 2020-08-25
JP2024037806A (ja) 2024-03-19
KR20260057219A (ko) 2026-04-27
CO2021010689A2 (es) 2021-08-30

Similar Documents

Publication Publication Date Title
JOP20210224A1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل)- بنزونيتريل
EP4338804A3 (en) Epinephrine spray formulations
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
MX2020009235A (es) Formulacion oftalmica.
MX2025000353A (es) Metodos para tratar el dolor de la superficie ocular
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
CL2021001956A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables. (divisional solicitud 202002624)
EA202092084A1 (ru) Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
SA519410324B1 (ar) صياغات رش إيبينيفرين
EA202092748A1 (ru) Модуляторы экспрессии apol1
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
MX2025006287A (es) Trehalosa para el tratamiento de la enfermedad de huntington
EA202190798A1 (ru) Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов
EA202193285A1 (ru) Состав с модифицированным высвобождением соединения пиримидиниламинопиразола и способы лечения
MX2022000349A (es) Cardioterápico.
EA202190891A1 (ru) Композиции и способы для контролируемой стимуляции яичников
EA202192418A1 (ru) Способы лечения al-амилоидоза
EA202190523A1 (ru) Замещенные индолы и способы их применения
EA201990712A1 (ru) Лечение рассеянного склероза посредством chs-131
EA202191927A1 (ru) Модуляторы gpr35